Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.34 |
| ▸ | CFB | P00751 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897789 | 0.90 | L3MBTL1 (0.36) | PIN1L3MBTL1ALKCFBGSK3B | |
| SCHEMBL1703702 | 0.88 | PIN1 (0.35) | PIN1L3MBTL1MMP13ALKCFB | |
| SCHEMBL897791 | 0.78 | CYP3A4 (0.38) | — | |
| SCHEMBL17434650 | 0.72 | ALK (0.38) | L3MBTL1ALKCFB | |
| SCHEMBL23639678 | 0.72 | L3MBTL1 (0.41) | PIN1L3MBTL1ALKGSK3B | |
| SCHEMBL897523 | 0.70 | MAPT (0.36) | L3MBTL1 | |
| SCHEMBL28319539 | 0.69 | L3MBTL1 (0.38) | PIN1L3MBTL1ALKGSK3B | |
| SCHEMBL6218634 | 0.66 | PIN1 (0.48) | PIN1L3MBTL1ALKMAPK10 | |
| SCHEMBL28588337 | 0.65 | PIN1 (0.45) | PIN1L3MBTL1ALK | |
| SCHEMBL24676630 | 0.65 | L3MBTL1 (0.38) | L3MBTL1ALKGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| WO-2010143664-A1 | TETRACYCLIC COMPOUND | 中外製薬株式会社 (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | PIN1 3353/4885L3MBTL1 200/4885MMP13 2597/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | PIN1 3353/4885L3MBTL1 200/4885MMP13 2597/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | PIN1 3353/4885L3MBTL1 200/4885MMP13 2597/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | PIN1 3353/4885L3MBTL1 200/4885MMP13 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.